Management of thrombosis in antiphospholipid antibody syndrome

Rheumatic Disease Clinics of North America

Volumn 27, Issue 3, 2001, Pages 633-642

  Petri, Michelle ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; TREATMENT INDICATION;

EID: 0034865787     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70225-8     Document Type: Article

References (38)

1. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome
2. Severe infections in plasmapheresis-treated systemic lupus erythematosus
3. The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A review of 31 patients
4. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases
5. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen
6. Streptokinase in acute ischemic stroke: An individual patient data meta- analysis: The Thrombolysis in Acute Stroke Pooling Project
7. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment
8. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G 20210A prothrombin mutation
9. The management of antiphospholipid syndrome
10. Antiphospholipid antibodies and venous thromboembolism
11. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
12. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome
13. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome
14. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome
15. The management of thrombosis in the antiphospholipid antibody syndrome
16. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis
17. Management of immune thrombocytopenic purpura associated with the antiphospholipid antibody syndrome
18. Antiphospholipid antibodies, anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders
19. Low molecular weight heparins and heparin-induced thrombocytopenia
20. Antiplatelet factor 4-heparin antibodies in patients with antiphospholipid antibodies
21. Monitoring warfarin therapy in patients with lupus anticoagulants
22. Successful thromboendarterectomy for chronic pulmonary embolism in a patient with systemic lupus erythematosus and antiphospholipid syndrome
23. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome
24. Antiphospholipid antibodies and venous thrombosis (VT) in SLE
25. Hydroxychloroquine: Past, present, future
26. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective
27. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
28. Anticardiolipin antibodies and clinical spectrum of antiphospholipid syndrome in patients with systemic lupus erythematosus
29. Antiphospholipid antibodies, recurrent thromboembolism and intensity of oral anticoagulation
30. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
31. Anticardiolipin antibodies and recurrent thromboembolism
32. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
33. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
34. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group
35. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group
36. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome
37. Cerebrovascular ischemic events with high positive anticardiolipin antibodies
38. 2-glycoprotein I antibodies in patients with acute venous thromboembolism: Prevalence and association with recurrent thromboembolism